Home > Newsletters > FDAnews Drug Daily Bulletin > FDA Reclassifies Clinical Hold on Repros’ Mid-Stage Endometriosis Trial
FDAnews Drug Daily Bulletin
Oct. 22, 2012 | Vol. 9 No. 207
FDA Reclassifies Clinical Hold on Repros’ Mid-Stage Endometriosis Trial
The FDA reclassified its clinical hold on Repros Therapeutics’ Proellex and will now allow the company to conduct a Phase II trial of low-dose Proellex as a treatment for endometriosis. The four-month study, which is on a partial clinical hold, will compare the reduction in need for narcotic analgesics in 90 women with severe endometriosis who are taking placebo, 6 mg or 12 mg Proellex (telapristone). Secondary endpoints of the trial will assess menstrual, nonmenstrual and intercourse-related pain.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.